Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
ES-NSCLC
Overall survival
SBRT
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
25
01
2024
accepted:
02
04
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
18
4
2024
Statut:
epublish
Résumé
Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC), but which patients benefit from stereotactic radiotherapy is unclear. The aim of this study was to analyze prognostic factors for early mortality. From August 2010 to 2022, 617 patients with medically inoperable, peripheral or central ES-NSCLC were treated with SABR at our institution. We retrospectively evaluated the data from 172 consecutive patients treated from 2018 to 2020 to analyze the prognostic factors associated with overall survival (OS). The biological effective dose was > 100 Gy The median OS was 35.3 months. In univariate analysis, no correlation was found between OS and ventilation parameters, histology, PET, or centrality. Tumor diameter, biological effective dose, gender, and AACCI met the criteria for inclusion in the multivariate analysis. The multivariate model showed that males (HR 1.51, 95% CI 1.01-2.28; p = 0.05) and AACCI > 5 (HR 1.56, 95% CI 1.06-2.31; p = 0.026) were significant negative prognostic factors of OS. However, the analysis of OS showed that the significant effect of AACCI > 5 was achieved only after 3 years (3-year OS 37% vs. 56%, p = 0.021), whereas the OS in one year was similar (1-year OS 83% vs. 86%, p = 0.58). SABR of ES-NSCLC with precise image guidance is feasible for all medically inoperable patients with reasonable performance status. Early deaths were rare in our real-life cohort, and OS is clearly higher than would have been expected after best supportive care.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC), but which patients benefit from stereotactic radiotherapy is unclear. The aim of this study was to analyze prognostic factors for early mortality.
METHODS
METHODS
From August 2010 to 2022, 617 patients with medically inoperable, peripheral or central ES-NSCLC were treated with SABR at our institution. We retrospectively evaluated the data from 172 consecutive patients treated from 2018 to 2020 to analyze the prognostic factors associated with overall survival (OS). The biological effective dose was > 100 Gy
RESULTS
RESULTS
The median OS was 35.3 months. In univariate analysis, no correlation was found between OS and ventilation parameters, histology, PET, or centrality. Tumor diameter, biological effective dose, gender, and AACCI met the criteria for inclusion in the multivariate analysis. The multivariate model showed that males (HR 1.51, 95% CI 1.01-2.28; p = 0.05) and AACCI > 5 (HR 1.56, 95% CI 1.06-2.31; p = 0.026) were significant negative prognostic factors of OS. However, the analysis of OS showed that the significant effect of AACCI > 5 was achieved only after 3 years (3-year OS 37% vs. 56%, p = 0.021), whereas the OS in one year was similar (1-year OS 83% vs. 86%, p = 0.58).
CONCLUSION
CONCLUSIONS
SABR of ES-NSCLC with precise image guidance is feasible for all medically inoperable patients with reasonable performance status. Early deaths were rare in our real-life cohort, and OS is clearly higher than would have been expected after best supportive care.
Identifiants
pubmed: 38637844
doi: 10.1186/s13014-024-02439-0
pii: 10.1186/s13014-024-02439-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : Ministry of Health, Czech Republic
ID : FNOs 2021
Organisme : Ministry of Health, Czech Republic
ID : FNOs 2021
Organisme : Ministry of Health, Czech Republic
ID : FNOs 2021
Informations de copyright
© 2024. The Author(s).
Références
Acta Oncol. 2018 Feb;57(2):226-230
pubmed: 29034756
Lung Cancer. 2019 Feb;128:127-133
pubmed: 30642444
Radiother Oncol. 2008 Sep;88(3):359-67
pubmed: 18768228
Cancers (Basel). 2022 Feb 13;14(4):
pubmed: 35205682
Radiother Oncol. 2021 Mar;156:223-230
pubmed: 33418006
J Thorac Oncol. 2015 Feb;10(2):264-71
pubmed: 25371079
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Radiother Oncol. 2014 Mar;110(3):499-504
pubmed: 24630539
Eur J Cardiothorac Surg. 2018 Jan 1;53(1):235-240
pubmed: 29106506
Radiother Oncol. 2009 Dec;93(3):402-7
pubmed: 19559492
Radiat Oncol. 2021 Jan 5;16(1):1
pubmed: 33402192
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Cancer. 2004 Oct 1;101(7):1623-31
pubmed: 15378503
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
J Cancer Res Clin Oncol. 2020 May;146(5):1263-1271
pubmed: 32095885
Radiother Oncol. 2016 Oct;121(1):1-8
pubmed: 27600155
Acta Oncol. 2019 Feb;58(2):237-242
pubmed: 30451552
J Thorac Oncol. 2016 Jul;11(7):1132-9
pubmed: 27060654
Clin Lung Cancer. 2019 Jan;20(1):e63-e71
pubmed: 30337269
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397